Futuresearch Trials of Dallas, Lp

Dallas, Texas 91316

2 studies enrolling now · 66 studies all time

What they study most

ADHD, Acute Migraine, Adjunctive Treatment of Major Depressive Disorder, Adult Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, Analgesia, Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit/Hyperactivity Disorder, Attention-deficit/Hyperactivity Disorder, Behavioral Variant Frontotemporal Dementia, Binge Eating Disorder, Central Nervous System Diseases

Studies at this site

• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Recruiting now
• RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA — Completed
• A Study to Test Different Doses of BI 1569912 in People With Depression — Completed
• A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder — Completed
• Zelquistinel in the Treatment of Major Depressive Disorder — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder — Completed
• A Study of Cytisinicline for Smoking Cessation in Adult Smokers — Completed
• Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens — Completed
• Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) — Completed
• A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder — Completed
• A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine — Completed
• A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention — Stopped early
• A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder — Completed
• A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder — Completed
• Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults — Completed
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
• A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine — Completed
• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia — Completed
• Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) — Stopped early
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
• Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine — Completed
• Randomized Trial in Adult Participants With Acute Migraines — Completed
• Trial in Adult Subjects With Acute Migraines — Completed
• Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine — Completed
• Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain — Completed
• Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder — Completed
• Open Label Extension in Adults With Binge Eating Disorder (BED) — Completed
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder — Completed
• Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) — Completed
• Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) — Completed
• A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression — Stopped early
• Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain — Completed
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL) — Completed
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• The Efficacy and Safety of PRC-063 in Adult ADHD Patients — Completed
• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• Long-term Open-Label Safety Study to Evaluate EN3409 — Completed
• Smoking Cessation Study In Healthy Adolescent Smokers — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed